A late clinical-stage
biopharmaceutical company
Stock code: XXXX.HK
We engage transparently with the financial community
on our science-driven strategy, performance,
and long-term outlook.
Latest News
-
OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
Read more -
OncoC4 announces first participant’s dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease
Read more -
BioNTech and OncoC4 Receive FDA Orphan Drug Designation for Gotistobart in Squamous Non-Small Cell Lung Cancer
Read more
